sections button arrow
AACR Chief Executive Officer Margaret Foti at the Annual Meeting Opening Ceremony

The AACR in 2024: A Look Ahead

tooltip iconAACR Chief Executive Officer Margaret Foti, PhD, MD (hc), presents the AACR’s vision during the Opening Ceremony at the AACR Annual Meeting 2023.

Inspiring Science. Fueling Progress. Revolutionizing Care.

AACR programs and initiatives have fostered collaboration, sparked innovation, and driven progress against cancer in the past year. In 2024, the AACR will continue to advance a bold scientific agenda in pursuit of its mission to prevent and cure all cancers.


Over the last several years, the AACR has taken dramatic steps to advance the field of hematological malignancies—from its initial 2018 collaboration with the Foundation for the Institute on Oncology Research (IOR) to develop the program for the long-running International Conference on Malignant Lymphoma, to the launch of its journal Blood Cancer Discovery in 2020, to the establishment of AACR Award for Outstanding Achievement in Blood Cancer Research in 2022. That leadership role will be expanded in 2024 with the founding of a new scientific working group.

The AACR Hematologic Malignancies Working Group—the ninth scientific working group founded by the AACR—will convene national and international leaders and stakeholders across all sectors engaged in hematologic malignancies research. The group’s mission will be to survey the current state of the field, identify opportunities for innovation to accelerate progress, and guide the AACR’s current and future programs focused on blood-based cancers and other related diseases. Kenneth C. Anderson, MD, FAACR, will serve as the inaugural chair of the working group, which will open to members during the AACR Annual Meeting 2024.

Patient advocates on stage during the Opening Ceremony at the AACR Annual Meeting 2023


In 2019, AACR Project GENIE® launched the Biopharma Collective (BPC), a five-year collaboration with a coalition of ten biopharmaceutical companies with the goal of obtaining clinical and genomic data from tens of thousands of de-identified patients treated at GENIE participating institutions. With phase 1 complete and phase 2 well underway, the collective plans to publicly release several clinically annotated, genomically profiled real-world datasets in 2024—including data from more than 1,200 early onset breast cancer patients.

arrow to previous page Financial Statement

Financial Statement